The cancer develops in the lungs and chest wall. It often progresses rapidly, and the first-year survival rate is only 12%, the drugmaker said. In a trial comparing cisplatin and pemetrexed versus Keytruda, cisplatin and pemetrexed, the latter achieved better results. The Keytruda group saw a 62% objective response rate, and the chemotherapy-only cohort had a 38% ORR.
The risk of death fell by 21% for the Keytruda-chemotherapy patients.
Based on the results, the FDA granted the experimental drug regimen with a priority review, and the agency is expected to make a decision by Sept. 25.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
